Sunitinib in hepatocellular carcinoma: redefining appropriate dosing, schedule, and activity end points.

Suppr

超能文献

作者信息

Faivre Sandrine J, Bouattour Mohamed, Dreyer Chantal, Raymond Eric

出版信息

J Clin Oncol. 2009 Dec 10;27(35):e248-50; author reply e251-2. doi: 10.1200/JCO.2009.25.0670. Epub 2009 Nov 9.

DOI:10.1200/JCO.2009.25.0670

PMID:19901099

Abstract

摘要

相似文献

Sunitinib in hepatocellular carcinoma: redefining appropriate dosing, schedule, and activity end points.

J Clin Oncol. 2009 Dec 10;27(35):e248-50; author reply e251-2. doi: 10.1200/JCO.2009.25.0670. Epub 2009 Nov 9.

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

J Clin Oncol. 2008 Aug 1;26(22):3743-8. doi: 10.1200/JCO.2007.15.5416.

Bridging Sunitinib Exposure to Time-to-Tumor Progression in Hepatocellular Carcinoma Patients With Mathematical Modeling of an Angiogenic Biomarker.

CPT Pharmacometrics Syst Pharmacol. 2016 Jun;5(6):297-304. doi: 10.1002/psp4.12084. Epub 2016 Jun 8.

Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.

Am J Clin Oncol. 2010 Jun;33(3):217-20. doi: 10.1097/COC.0b013e3181a650a6.

Durable complete response of hepatocellular carcinoma after metronomic capecitabine.

Tumori. 2010 Nov-Dec;96(6):1028-30.

Sunitinib malate in patients with intermediate-2 or high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia.

Leuk Lymphoma. 2014 Nov;55(11):2669-71. doi: 10.3109/10428194.2014.900763. Epub 2014 Apr 22.

Imbalance and gait disturbance from tyrosine kinase inhibition in hepatocellular cancer.

J Gastrointest Cancer. 2009;40(3-4):119-22. doi: 10.1007/s12029-009-9086-7.

Sunitinib in urothelial cancer: clinical, pharmacokinetic, and immunohistochemical study of predictors of response.

Eur Urol. 2011 Aug;60(2):344-9. doi: 10.1016/j.eururo.2011.05.034. Epub 2011 May 25.

Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: kinetics and potential biomarker value.

Clin Cancer Res. 2011 Feb 15;17(4):918-27. doi: 10.1158/1078-0432.CCR-10-0515. Epub 2010 Sep 15.

KS trial begins.

AIDS Patient Care STDS. 2000 Jun;14(6):338.

引用本文的文献

Sunitinib as Second-Line Treatment in Advanced Intrahepatic Cholangiocarcinoma: Results From the SUN-CK GERCOR Phase II Trial.

Liver Int. 2025 Aug;45(8):e70196. doi: 10.1111/liv.70196.

Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors.

Front Immunol. 2020 Jan 21;10:3038. doi: 10.3389/fimmu.2019.03038. eCollection 2019.

Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma.

Clin Pharmacokinet. 2019 Aug;58(8):983-1014. doi: 10.1007/s40262-019-00740-w.

Sunitinib represses regulatory T cells to overcome immunotolerance in a murine model of hepatocellular cancer.

Oncoimmunology. 2017 Sep 21;7(1):e1372079. doi: 10.1080/2162402X.2017.1372079. eCollection 2017.

Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma.

Hepatology. 2018 Mar;67(3):1132-1149. doi: 10.1002/hep.29496. Epub 2018 Feb 1.

Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging.

World J Hepatol. 2015 Sep 18;7(20):2245-63. doi: 10.4254/wjh.v7.i20.2245.

Initial response to sorafenib by using enhancement criteria in patients with hepatocellular carcinoma.

Hepatol Int. 2013 Jun;7(2):703-13. doi: 10.1007/s12072-013-9425-4. Epub 2013 Feb 12.

Disease control with sunitinib in advanced intrahepatic cholangiocarcinoma resistant to gemcitabine-oxaliplatin chemotherapy.

World J Hepatol. 2015 Apr 28;7(6):910-5. doi: 10.4254/wjh.v7.i6.910.

Vessel caliber--a potential MRI biomarker of tumour response in clinical trials.

Nat Rev Clin Oncol. 2014 Oct;11(10):566-84. doi: 10.1038/nrclinonc.2014.126. Epub 2014 Aug 12.

Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib.

Oncologist. 2014 Apr;19(4):394-402. doi: 10.1634/theoncologist.2013-0114. Epub 2014 Mar 20.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验